| NCT05984953 | Icahn School of Medicine at Mount Sinai | Coronary Artery Disease | 2013-08-01 | |
| NCT01953328 | Amgen | Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events | 2013-10 | PHASE3 |
| NCT01624142 | Amgen | Severe Familial Hypercholesterolemia | 2012-06-01 | PHASE2|PHASE3 |
| NCT03331666 | Columbia University|Amgen | Familial Hypercholesterolemia | 2018-11-16 | PHASE4 |
| NCT05974345 | Novartis Pharmaceuticals | Atherosclerotic Cardiovascular Disease | 2023-11-03 | |
| NCT06700720 | Beijing Inno Medicine Co., Ltd. | Coronary Artery Disease|Coronary Atherosclerotic Disease | 2026-02 | PHASE2 |
| NCT03500302 | Johns Hopkins University|American Heart Association | Human Immunodeficiency Virus|Coronary Artery Disease | 2018-05-04 | PHASE2 |
| NCT04510844 | NYU Langone Health | Chronic Kidney Diseases|High Cholesterol | 2021-03-01 | PHASE4 |
| NCT05697185 | Second Affiliated Hospital of Guangxi Medical University | Ischemic Stroke, Acute | 2023-02-01 | PHASE4 |
| NCT05284747 | Amgen|Colorado Prevention Center | Cardiovascular Disease|Myocardial Infarction|Stroke|Coronary Revascularization | 2022-10-26 | PHASE4 |
| NCT03258281 | Inova Health Care Services | Diabetes Mellitus, Type 2|Dyslipidemia Associated With Type II Diabetes Mellitus|Percutaneous Coronary Intervention | 2018-05-01 | PHASE4 |
| NCT01588496 | Amgen | Homozygous Familial Hypercholesterolemia | 2012-04-05 | PHASE2|PHASE3 |
| NCT06740552 | Shanghai Zhongshan Hospital|Shanghai Shenkang Hospital Development Center|Tongji Hospital|RenJi Hospital|Shanghai 10th People´s Hospital|Shanghai General Hospital, China | Multivessel Coronary Artery Disease|Acute Myocardial Infarction (AMI) | 2021-01-01 | |
| NCT01133522 | Amgen | Hyperlipidemia | 2010-06-01 | PHASE1 |
| NCT04941105 | Collegium Medicum w Bydgoszczy | Sars-CoV-2 Infection | 2021-06-01 | PHASE3 |
| NCT04790513 | LIB Therapeutics LLC | Hypercholesterolemia|Cardiovascular Diseases | 2021-04-22 | PHASE3 |
| NCT02585895 | Amgen | Hypercholesterolemia | 2015-12-21 | PHASE3 |
| NCT06858332 | Novartis Pharmaceuticals | Atherosclerotic Cardiovascular Disease | 2025-04-15 | |
| NCT04034485 | LIB Therapeutics LLC | Homozygous Familial Hypercholesterolemia | 2019-12-07 | PHASE3 |
| NCT01380730 | Amgen|The TIMI Study Group | Hyperlipidemia | 2011-07-01 | PHASE2 |
| NCT03689946 | Cedars-Sinai Medical Center|Amgen | Cardiovascular Disease|Hyperlipidemia | 2019-03-19 | PHASE3 |
| NCT02634580 | Amgen | Hypercholesterolemia | 2016-02-27 | PHASE3 |
| NCT04951856 | Assistance Publique - H?pitaux de Paris|Action Research Group|Amgen | STEMI - ST Elevation Myocardial Infarction|NSTEMI - Non-ST Segment Elevation MI | 2021-09-29 | PHASE4 |
| NCT04303377 | Fondazione IRCCS Policlinico San Matteo di Pavia|Centro Cardiologico Monzino|Ospedale Bassini Cinisello Balsamo|Azienda Ospedaliera Ordine Mauriziano di Torino|Ospedale Policlinico San Martino|Fondazione Poliambulanza Istituto Ospedaliero|Azienda Ospedaliera San Gerardo di Monza|Azienda Ospedaliera Sant´Anna e San Sebastiano|Azienda Ospedaliera, Ospedale Civile di Legnano | ST-elevation Myocardial Infarction | 2019-11-18 | PHASE2 |
| NCT03851263 | ECRI bv|Amgen|GE Healthcare|HeartFlow, Inc. | Coronary Artery Disease | 2019-08-30 | PHASE4 |
| NCT03811223 | UMC Utrecht|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Erasmus Medical Center|University Medical Center Nijmegen | Familial Dysbetalipoproteinemia|Hyperlipoproteinemia Type III | 2019-08 | PHASE4 |
| NCT03247972 | Inova Health Care Services | Peripheral Arterial Disease | 2017-08-11 | |
| NCT02941016 | Rigshospitalet, Denmark | Lipid Lowering, Vascular Inflammation | 2016-10 | PHASE4 |
| NCT04100434 | Tianjin Chest Hospital | Acute Coronary Syndrome|Proprotein Convertase Subtilisin+Kexin Type 9 Inhibitor | 2021-01-01 | PHASE4 |
| NCT05976893 | Xiang Xie|Xinjiang Medical University | ASCVD|Atherosclerotic Cardiovascular Disease|Proprotein Convertase Subtilisin+Kexin Type 9 Inhibitor|Cancer | 2023-08-01 | PHASE4 |
| NCT03337698 | Hoffmann-La Roche | Carcinoma, Non-Small-Cell Lung | 2017-12-27 | PHASE1|PHASE2 |
| NCT05144529 | Eziafa Oduah, MD, PhD, MPH | Lung Cancer Metastatic | 2022-03-22 | PHASE2 |
| NCT03429998 | Hospital General Universitario Gregorio Mara?on | Hypercholesterolemia | 2017-04-01 | PHASE3 |
| NCT06134635 | Xuanwu Hospital, Beijing | Acute Ischemic Stroke | 2023-12-01 | |
| NCT04608474 | Brigham and Women´s Hospital|Amgen | Hyperlipidemias | 2021-02-17 | PHASE4 |
| NCT03626831 | University of Erlangen-Nürnberg Medical School | Atherosclerotic Cardiovascular Disease | 2019-04-04 | PHASE4 |
| NCT03433755 | Amgen | Primary Hypercholesterolemia|Mixed Dyslipidemia | 2019-05-09 | PHASE3 |
| NCT05661552 | Yonsei University|Daewoong Pharmaceutical Co. LTD. | Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia | 2022-12-01 | PHASE4 |
| NCT02275156 | Amgen | Hyperlipidemia|Mixed Dyslipidemia | 2014-08-19 | PHASE1 |
| NCT04397653 | Policlinico Casilino ASL RMB|IRCCS San Raffaele | Hypercholesterolemia|Chronic Kidney Disease Requiring Chronic Dialysis | 2020-05-04 | PHASE4 |
| NCT02729025 | Amgen | Subjects With Hyperlipidemia, Dyslipidemia | 2016-04-14 | PHASE3 |
| NCT02392559 | Amgen | Heterozygous Familial Hypercholesterolemia | 2016-03-24 | PHASE3 |
| NCT04101643 | First Affiliated Hospital of Fujian Medical University | Hereditary Spastic Paraplegia Type 5 | 2019-09-29 | PHASE1|PHASE2 |
| NCT04087915 | Beijing Anzhen Hospital | Dyslipidemia|High Risk Coronary Artery Disease | 2019-09-11 | |
| NCT07545226 | Amgen | Healthy Participants | 2026-04-20 | PHASE1 |
| NCT03900026 | Unity Health Toronto|Applied Health Research Centre | Coronary Artery Bypass Graft Surgery|Atherosclerosis|Vein Occlusion | 2019-05-30 | PHASE4 |
| NCT03080935 | Amgen | Dyslipidemia | 2017-03-13 | PHASE3 |
| NCT03734211 | Lars Gullestad|Sahlgrenska University Hospital|Skane University Hospital|Rigshospitalet, Denmark|Aarhus University Hospital|Helsinki University Central Hospital | Cardiac Allograft Vasculopathy | 2019-06-10 | PHASE3 |
| NCT07036991 | Changhai Hospital|The First Affiliated Hospital of Soochow University | Carotid Artery Stenosis | 2025-07-30 | PHASE4 |
| NCT04730973 | Azienda Ospedaliera Ordine Mauriziano di Torino | Carotid Artery Disease | 2021-03-01 | PHASE4 |
| NCT04313270 | Federico II University | Hypercholesterolemia, Familial | 2017-12-01 | |
| NCT05741086 | The First Affiliated Hospital with Nanjing Medical University | Stroke Patients With Symptomatic Intracranial Atherosclerotic Stenosis | 2023-04-15 | PHASE3 |
| NCT02957604 | Amgen|Organization of Teratology Information Specialists (OTIS) Research Center - tel: 1-866-626-6847 or www.mothertobaby.org | Hypercholesterolemia; ASCVD; Pregnancy | 2016-12-22 | |
| NCT05802108 | Zibo Central Hospital | Adverse Effect of Cardiovascular Medications (Diagnosis) | 2022-07-01 | PHASE4 |
| NCT02833844 | Amgen | Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection | 2017-05-22 | PHASE3 |
| NCT03944577 | University of Nebraska|Amgen | Heart Transplant | 2019-07-15 | PHASE2 |
| NCT01763905 | Amgen | Hyperlipidemia | 2013-01-24 | PHASE3 |
| NCT04306471 | Leonardo Clavijo|Amgen | Critical Limb Ischemia | 2020-02-24 | PHASE4 |
| NCT04613167 | University Medical Centre Ljubljana | Acute Coronary Syndrome|Premature Coronary Heart Disease|Lipoproteinemia|Inflammation|Genetic Polymorphisms | 2020-11-10 | NA |
| NCT04338165 | University Hospital, Grenoble | Atherosclerotic Cardiovascular Disease | 2021-01-08 | PHASE2 |
| NCT04189484 | Food and Drug Administration (FDA)|Spaulding Clinical Research LLC | Healthy Subjects|Pharmacokinetics|Pharmacodynamics | 2020-01-07 | PHASE1 |
| NCT06364124 | Beijing Luhe Hospital | STEMI | 2023-06-01 | NA |
| NCT03403374 | Amgen | Homozygous Familial Hypercholesterolemia HoFH | 2018-08-04 | PHASE4 |
| NCT02304484 | Amgen | Hypercholesterolemia | 2014-11-24 | PHASE3 |
| NCT01813422 | Amgen | Hypercholesterolemia | 2013-04-18 | PHASE3 |
| NCT03570697 | Amgen | Coronary Artery Disease (CAD) | 2018-11-19 | PHASE3 |
| NCT02624869 | Amgen | Familial Hypercholesterolemia | 2016-09-10 | PHASE3 |
| NCT04539223 | Canadian Medical and Surgical Knowledge Translation Research Group|Amgen | Carotid Artery Stenosis|Asymptomatic Carotid Artery Stenosis | 2020-08-28 | PHASE4 |
| NCT04719221 | Korea University Anam Hospital | Clinical Trial|Acute Coronary Syndrome | 2021-03-01 | PHASE4 |
| NCT06140095 | Region Stockholm|Amgen | Acute Metabolic Effects of Evolocumab and Atorvastatin | 2024-02 | EARLY_PHASE1 |
| NCT03060577 | Novartis Pharmaceuticals | Atherosclerotic Cardiovascular Disease|Symptomatic Atherosclerosis|Type2 Diabetes|Familial Hypercholesterolemia | 2017-04-27 | PHASE2 |
| NCT04082442 | Johns Hopkins University|Amgen | Acute Coronary Syndrome | 2019-09-01 | PHASE2 |
| NCT05613426 | Henan Institute of Cardiovascular Epidemiology | ST Elevation Myocardial Infarction (STEMI) | 2023-04-03 | PHASE4 |
| NCT01849497 | Amgen | Primary Hypercholesterolemia|Mixed Dyslipidemia | 2013-04-18 | PHASE3 |
| NCT03932721 | University of Campinas, Brazil | Dyslipidemia Associated With Type II Diabetes Mellitus|Diabetes Mellitus, Type 2|Hypertension Arterial | 2018-10-01 | PHASE4 |
| NCT03193047 | Esperion Therapeutics, Inc. | Hypercholesterolemia | 2017-04-07 | PHASE2 |
| NCT01375777 | Amgen | Hyperlipidemia | 2011-07-06 | PHASE2 |
| NCT03515304 | Johns Hopkins University|Amgen | Acute Coronary Syndrome | 2018-05-20 | PHASE2 |
| NCT05587621 | Jena University Hospital | ST Elevation Myocardial Infarction|Non-ST Elevation Myocardial Infarction|LDL-cholesterol | 2024-04-01 | NA |
| NCT06231459 | Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado | Hypercholesterolemia, Familial | 2019-01-01 | PHASE4 |
| NCT04659525 | Policlinico Casilino ASL RMB|IRCCS San Raffaele | Hypercholesterolemia|CKD Stage 5|Chronic Kidney Disease Requiring Chronic Dialysis | 2020-11-01 | PHASE4 |
| NCT03872401 | Amgen | Coronary Heart Disease (CHD) | 2019-06-11 | PHASE3 |
| NCT02948777 | Marja-Riitta Taskinen|G?teborg University | Type 2 Diabetes Mellitus | 2016-10 | PHASE4 |
| NCT03287609 | Insel Gruppe AG, University Hospital Bern|Amgen|University of Bern | Acute Coronary Syndrome | 2018-01-23 | PHASE3 |
| NCT01763866 | Amgen | Hyperlipidemia | 2013-01-15 | PHASE3 |
| NCT07422285 | Amgen | Healthy Participants|Pharmacokinetics | 2026-01-16 | PHASE1 |
| NCT02207634 | Amgen | Dyslipidemia | 2014-09-10 | PHASE3 |
| NCT01984424 | Amgen | Hyperlipidemia | 2013-12-10 | PHASE3 |
| NCT01763827 | Amgen | Hyperlipidemia | 2013-01-21 | PHASE3 |
| NCT01516879 | Amgen | Hypercholesterolemia | 2012-01-05 | PHASE3 |
| NCT04937413 | Duke University | Malignant Glioma|Glioblastoma | 2021-10-08 | EARLY_PHASE1 |
| NCT05579418 | Hamad Medical Corporation | STEMI|Dyslipidemias | 2022-11-01 | PHASE4 |
| NCT05418166 | First Affiliated Hospital of Harbin Medical University | Acute Coronary Syndrome | 2021-12-23 | |
| NCT01375764 | Amgen | Hyperlipidemia | 2011-07-28 | PHASE2 |
| NCT02189837 | Amgen | Primary Hyperlipidemia and Mixed Dyslipidemia | 2014-07-08 | PHASE3 |
| NCT02739984 | Amgen | Hypercholesterolemia|Mixed Dyslipidemia|Type 2 Diabetes | 2016-05-17 | PHASE3 |
| NCT04141579 | Radboud University Medical Center|Amgen | Coronary Artery Disease|Atherosclerosis of Coronary Artery | 2020-11-10 | NA |
| NCT01652703 | Amgen | Hypercholesterolemia and High Risk for Cardiovascular Events | 2012-07-10 | PHASE2 |
| NCT01763918 | Amgen | Hyperlipidemia | 2013-02-07 | PHASE3 |
| NCT03829046 | Robert Rosenson|Amgen|University of Toronto|University of Michigan | Atherosclerotic Vascular Disease|Type2 Diabetes|Microvascular Dysfunction | 2019-06-03 | PHASE4 |
| NCT02867813 | Amgen | Dyslipidemia | 2016-09-02 | PHASE3 |
| NCT04710368 | Annapoorna Kini | Coronary Artery Disease | 2021-05-04 | PHASE4 |
| NCT03869073 | University of British Columbia | Sepsis | 2019-02-11 | PHASE2 |
| NCT01375751 | Amgen | Hypercholesterolemia, Familial | 2011-08-02 | PHASE2 |
| NCT04306081 | Leonardo Clavijo|Amgen | Peripheral Arterial Disease | 2017-12-14 | PHASE4 |
| NCT07388420 | General Hospital of Shenyang Military Region | Hypertriglyceridemia Induced Acute Pancreatitis | 2026-01-02 | NA |
| NCT04073134 | Imperial College London | Coronary Artery Disease|Atherosclerosis|Hyperlipidemias | 2019-09-11 | PHASE4 |
| NCT03791593 | Fundació Institut Germans Trias i Pujol | Heart Failure With Reduced Ejection Fraction | 2018-12-03 | PHASE2 |
| NCT01439880 | Amgen | Hypercholesterolemia | 2011-10-07 | PHASE2 |
| NCT03096288 | University of Florida|Amgen | Atherosclerotic Cardiovascular Disease | 2017-10-03 | PHASE4 |
| NCT01854918 | Amgen | Hyperlipidemia and Mixed Dyslipidemia | 2013-04-23 | PHASE3 |
| NCT05152888 | Brigham and Women´s Hospital | Stable Coronary Disease | 2022-03-03 | PHASE4 |
| NCT01879319 | Amgen | Primary Hypercholesterolemia|Mixed Dyslipidemia | 2013-07-11 | PHASE3 |
| NCT04992065 | Novo Nordisk A+S | Atherosclerotic Cardiovascular Disease | 2021-08-03 | PHASE2 |
| NCT05641753 | NYU Langone Health|National Heart, Lung, and Blood Institute (NHLBI) | Type 1 Diabetes | 2022-12-06 | PHASE4 |
| NCT03931161 | Imperial College Healthcare NHS Trust|Imperial College London | Carotid Artery Stenosis | 2019-09-04 | PHASE4 |
| NCT05184530 | First Affiliated Hospital Xi´an Jiaotong University | Coronary Disease | 2016-01 | |
| NCT01764633 | Amgen | Dyslipidemia | 2013-02-08 | PHASE3 |
| NCT06284564 | M.D. Anderson Cancer Center|Bristol-Myers Squibb|Cancer Prevention Research Institute of Texas|United States Department of Defense | Metastatic Renal Cell Carcinoma | 2024-08-07 | PHASE2 |
| NCT04665830 | Hamid Al-Essa Organ Transplant Center | Kideny Transplant Recipients With High Cardiovascular Risk Score | 2018-05-01 | PHASE3 |
| NCT05585151 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Cerebral Atherosclerosis | 2022-11-09 | PHASE4 |
| NCT02662569 | Amgen | Diabetes, Hyperlipidemia, Mixed Dyslipidemia | 2016-04-14 | PHASE3 |
| NCT06081153 | University of Pennsylvania|National Heart, Lung, and Blood Institute (NHLBI)|Amgen | Abdominal Aortic Aneurysm | 2026-12-01 | EARLY_PHASE1 |